TACE: TACE, 15,000U bleomycin and 200-400μm drug-loaded microspheres
Study summary
transarterial bleomycin chemoembolization represents a novel minimally invasive therapeutic approach for the management of giant nodular goiter.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Clinical criteria: thyroid enlargement, mostly painless, with compressive symptoms (such as dysphagia, dyspnea) being less common; thyroid function is mostly normal, and a small number may be accompanied by hyperthyroidism or hypothyroidism.
* Imaging examinations: ultrasound shows multiple solid or cystic-solid nodules with clear boundaries and no malignant signs such as microcalcification and a vertical-to-horizontal diameter ratio \>1.
* Pathological criteria: follicular epithelial cell hyperplasia, no nuclear atypia, and no malignant cellular characteristics (such as mitotic figures, infiltrative growth, etc.). In this study, a thyroid goiter with at least one diameter exceeding 4 cm was considered a giant goiter
Exclusion Criteria:
* abnormal coagulation profiles;
* hepatic or renal impairment;
* allergy to contrast media;
* refusal of interventional therapy and requirement for surgical treatment or other therapies
Primary outcome measure(s)
volume — 1-, 3-, 6-, 12-month follow up Lesion volume measurement on contrast-enhanced CT
Trial sites (1)
Facility
City
Region
Status
Peking Union Medical College Hospital
Beijing
China
More Peking Union Medical College Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.